Originally started in 2010, Oncotarget began its humble beginnings and its origins as a traditional multidisciplinary journal with a severe focus on oncology.
There is one particular core value that makes Oncotarget stand out from most other journals: democratization.
Oncotarget has further demonstrated that it takes democratization seriously with the implementation of the Creative Commons Attribution 3.0 License.
This license allows fellow researchers to take the research studies from Oncotarget that are already published and share those published reports with other scientists in that field or in other fields that are of similiar or related interest.
One factor that is important to take into account is that Oncotarget focuses on more than just oncology primarily.
There are other topics of importance are of interest for Oncotarget such as gerotargeting, immunology, and other topics, as well.
Because of this open and free nature of how the research papers can be shared through the journal altogether, this allows for certain experiments to be finsihed more faster than it would if the published papers were more in a non-democratized manner.
— Oncotarget (@OncotargetJrnl) December 12, 2017
The other side benefit is that this saves time.
Oncotarget is constantly staying up-to-current-affairs by archiving published experiments each and every day.
The democratization nature of free and open access is a core principle that Oncotarget abides by greatly. Follow Oncotarget on Twitter.
Showcasing Promise for Oncotarget in the Media Landscape
Oncotarget proceeds with its stated objectives in regards to its media platform.
In 2017, Oncotarget had stated earlier that their objective was to effectively and efficiently transform the journal altogether into a twice-weekly publication.
One notable and aforementioned achievement has been reached.
The result of this glorious achievements is that there has been noticeable increase the frequency of their publication.
Because of this sudden increase that was planned, the media consumers won’t have to worry about hiatuses or gaps in their journal publications.
The next accomplishment is that Oncotarget has created its own podcast. The overall purpose of that podcast is to detail its findings in podcasting format.
Not everyone has the free time to read through various pages and pages of scientific papers.
Through the podcasting platform, people would be able to listen to latest developments through podcast, which is available on the following podcasting platforms such as Stitcher, Soundcloud, Player.FM, and iTunes.
Learn more: https://www.ncbi.nlm.nih.gov/pmc/journals/1558/
Oncotarget has also accomplish other achievements, too.
One particular great note of achievement is that a few Oncotarget researchers have been able to identify new therapeutic strategies to treat thyroid cancer.
Oncotarget is still remaining indexed by most scientific databases such as Scopus, Biological Abstracts, Embase, and BIOSIS Previews.
While not mainstream publicized, Oncotarget’s accomplishments have not gone unnoticed.
Because of the free and open nature that Oncotarget upholds, people are still able to move along with their experiments at a much more faster rate as opposed to the previous setting of having a close journal where rarely any experiments are shared.
The breakthroughs and the amount of published experiments are thankful for the success of the Oncotarget’s democratized approach. Learn more about Oncotarget at Eurekalert.org.